FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2601921625> ?p ?o ?g. }

• W2601921625 endingPage "33085" @default.
• W2601921625 startingPage "33078" @default.
• W2601921625 abstract "// Askar Obulkasim 1 , Jenny E. Katsman-Kuipers 1 , Lonneke Verboon 1 , Mathijs Sanders 2 , Ivo Touw 2 , Mojca Jongen-Lavrencic 2 , Rob Pieters 1, 3 , Jan-Henning Klusmann 4 , C. Michel Zwaan 1 , Marry M. van den Heuvel-Eibrink 1, 3 , Maarten Fornerod 1 1 Pediatric Oncology-Hematology, Erasmus MC, Sophia Children’s Hospital, The Netherlands 2 Department of Hematology, ErasmusMC, Rotterdam, The Netherlands 3 Prinses Máxima Center for Pediatric Oncology, Utrecht, The Netherlands 4 Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany Correspondence to: Maarten Fornerod, email: m.fornerod@erasmusmc.nl Keywords: microRNA, acute myeloid leukemia, pediatric, classification, cytogenetic aberration Received: October 27, 2016      Accepted: March 01, 2017      Published: March 23, 2017 ABSTRACT Pediatric acute myeloid leukemia (AML) is a heterogeneous disease with respect to biology as well as outcome. In this study, we investigated whether known biological subgroups of pediatric AML are reflected by a common microRNA (miRNA) expression pattern. We assayed 665 miRNAs on 165 pediatric AML samples. First, unsupervised clustering was performed to identify patient clusters with common miRNA expression profiles. Our analysis unraveled 14 clusters, seven of which had a known (cyto-)genetic denominator. Finally, a robust classifier was constructed to discriminate six molecular aberration groups: 11q23-rearrangements, t(8;21)(q22;q22), inv(16)(p13q22), t(15;17) (q21;q22), NPM1 and CEBPA mutations. The classifier achieved accuracies of 89%, 95%, 95%, 98%, 91% and 96%, respectively. Although lower sensitivities were obtained for the NPM1 and CEBPA (32% and 66%), relatively high sensitivities (84%−94%) were attained for the rest. Specificity was high in all groups (87%−100%). Due to a robust double-loop cross validation procedure employed, the classifier only employed 47 miRNAs to achieve the aforementioned accuracies. To validate the 47 miRNA signatures, we applied them to a publicly available adult AML dataset. Albeit partial overlap of the array platforms and molecular differences between pediatric and adult AML, the signatures performed reasonably well. This corroborates our claim that the identified miRNA signatures are not dominated by sample size bias in the pediatric AML dataset. In conclusion, cytogenetic subtypes of pediatric AML have distinct miRNA expression patterns. Reproducibility of the miRNA signatures in adult dataset suggests that the respective aberrations have a similar biology both in pediatric and adult AML." @default.
• W2601921625 created "2017-04-07" @default.
• W2601921625 creator A5008445390 @default.
• W2601921625 creator A5019814633 @default.
• W2601921625 creator A5021161172 @default.
• W2601921625 creator A5030406251 @default.
• W2601921625 creator A5033811992 @default.
• W2601921625 creator A5035292815 @default.
• W2601921625 creator A5035945818 @default.
• W2601921625 creator A5049314200 @default.
• W2601921625 creator A5064026375 @default.
• W2601921625 creator A5065897052 @default.
• W2601921625 creator A5070507977 @default.
• W2601921625 date "2017-03-23" @default.
• W2601921625 modified "2023-09-26" @default.
• W2601921625 title "Classification of pediatric acute myeloid leukemia based on miRNA expression profiles" @default.
• W2601921625 cites W1935726541 @default.
• W2601921625 cites W1966019264 @default.
• W2601921625 cites W1966116761 @default.
• W2601921625 cites W1974119365 @default.
• W2601921625 cites W1974369317 @default.
• W2601921625 cites W1975258982 @default.
• W2601921625 cites W1985563073 @default.
• W2601921625 cites W1996441871 @default.
• W2601921625 cites W1997338207 @default.
• W2601921625 cites W2013130094 @default.
• W2601921625 cites W2017971576 @default.
• W2601921625 cites W2021663709 @default.
• W2601921625 cites W2030579061 @default.
• W2601921625 cites W2032235087 @default.
• W2601921625 cites W2035643006 @default.
• W2601921625 cites W2049344510 @default.
• W2601921625 cites W2049963512 @default.
• W2601921625 cites W2051126469 @default.
• W2601921625 cites W2056777862 @default.
• W2601921625 cites W2063080163 @default.
• W2601921625 cites W2068839651 @default.
• W2601921625 cites W2069021280 @default.
• W2601921625 cites W2069923423 @default.
• W2601921625 cites W2083131489 @default.
• W2601921625 cites W2084166559 @default.
• W2601921625 cites W2096319802 @default.
• W2601921625 cites W2104517740 @default.
• W2601921625 cites W2107398329 @default.
• W2601921625 cites W2109703672 @default.
• W2601921625 cites W2110318292 @default.
• W2601921625 cites W2121565126 @default.
• W2601921625 cites W2123680400 @default.
• W2601921625 cites W2124605552 @default.
• W2601921625 cites W2130864403 @default.
• W2601921625 cites W2140929964 @default.
• W2601921625 cites W2151222524 @default.
• W2601921625 cites W2161150935 @default.
• W2601921625 cites W2166531817 @default.
• W2601921625 cites W2167468830 @default.
• W2601921625 cites W2169495247 @default.
• W2601921625 cites W2253167439 @default.
• W2601921625 cites W2419140434 @default.
• W2601921625 doi "https://doi.org/10.18632/oncotarget.16525" @default.
• W2601921625 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5464851" @default.
• W2601921625 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28380436" @default.
• W2601921625 hasPublicationYear "2017" @default.
• W2601921625 type Work @default.
• W2601921625 sameAs 2601921625 @default.
• W2601921625 citedByCount "11" @default.
• W2601921625 countsByYear W26019216252018 @default.
• W2601921625 countsByYear W26019216252019 @default.
• W2601921625 countsByYear W26019216252020 @default.
• W2601921625 countsByYear W26019216252022 @default.
• W2601921625 countsByYear W26019216252023 @default.
• W2601921625 crossrefType "journal-article" @default.
• W2601921625 hasAuthorship W2601921625A5008445390 @default.
• W2601921625 hasAuthorship W2601921625A5019814633 @default.
• W2601921625 hasAuthorship W2601921625A5021161172 @default.
• W2601921625 hasAuthorship W2601921625A5030406251 @default.
• W2601921625 hasAuthorship W2601921625A5033811992 @default.
• W2601921625 hasAuthorship W2601921625A5035292815 @default.
• W2601921625 hasAuthorship W2601921625A5035945818 @default.
• W2601921625 hasAuthorship W2601921625A5049314200 @default.
• W2601921625 hasAuthorship W2601921625A5064026375 @default.
• W2601921625 hasAuthorship W2601921625A5065897052 @default.
• W2601921625 hasAuthorship W2601921625A5070507977 @default.
• W2601921625 hasBestOaLocation W26019216251 @default.
• W2601921625 hasConcept C104317684 @default.
• W2601921625 hasConcept C126322002 @default.
• W2601921625 hasConcept C143998085 @default.
• W2601921625 hasConcept C145059251 @default.
• W2601921625 hasConcept C194409129 @default.
• W2601921625 hasConcept C203014093 @default.
• W2601921625 hasConcept C2483381 @default.
• W2601921625 hasConcept C2776601000 @default.
• W2601921625 hasConcept C2778729363 @default.
• W2601921625 hasConcept C2781121885 @default.
• W2601921625 hasConcept C30481170 @default.
• W2601921625 hasConcept C45091340 @default.
• W2601921625 hasConcept C53226629 @default.
• W2601921625 hasConcept C54355233 @default.
• W2601921625 hasConcept C60644358 @default.

• next